Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
- Conditions
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 308
- Registration Number
- NCT04538664
- Locations
- 🇲🇽
Centro Oncologico de Chihuahua, Chihuahua, Mexico
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California Irvine, Orange, California, United States
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 101
- Registration Number
- NCT04533451
- Locations
- 🇺🇸
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States
🇺🇸Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States
🇺🇸ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-11-13
- Target Recruit Count
- 30
- Registration Number
- NCT04530227
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 57
- Registration Number
- NCT04524689
- Locations
- 🇪🇸
Investigational Site Number : 7240005, La Coruña, A Coruña [La Coruña], Spain
🇪🇸Investigational Site Number : 7240006, Badalona, Catalunya [Cataluña], Spain
🇧🇷Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760004, Natal, Rio Grande Do Norte, Brazil
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 4
- Registration Number
- NCT04512430
- Locations
- 🇪🇸
ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario Insular de Gran canaria, Las Palmas De Gran Canaria, Gran Canaria, Spain
🇪🇸Complejo Hospitalario de Navarra, Pamplona, Iruña, Spain
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Shirish M Gadgeel
- Registration Number
- NCT04470674
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-07-12
- Target Recruit Count
- 60
- Registration Number
- NCT04459611
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2020-07-02
- Target Recruit Count
- 168
- Registration Number
- NCT04455594
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-01
- Target Recruit Count
- 90
- Registration Number
- NCT04453423
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 19
- Registration Number
- NCT04452214
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.